Hot Features
Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.
Prospect Medical Holdings, Inc. (Nasdaq: PZZ) (“Prospect” or the “Company”) today announced that, at the special meeting of stockholders held today, its stockholders approved...
Prospect Medical Holdings, Inc. (Nasdaq: PZZ) (“Prospect” or the “Company”) today announced the expiration of the 40-day “go-shop” period during which Prospect solicited...
Goldfarb Branham LLP is pursuing shareholder claims against the board of Prospect Medical Holdings (NASDAQ: PZZ) in connection with the proposed buyout. The acquisition will...
As previously announced, Robbins Umeda LLP has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by members of the Board of...
The Law Office of Jonathan M. Stein, P.L. is investigating the Board of Directors of Prospect Medical Holdings, Inc. ("Prospect Medical" or the "Company") (Nasdaq: PZZ) for...
Bull & Lifshitz, LLP announces an investigation into possible breaches of fiduciary duty in connection with the proposed acquisition of Prospect Medical Holdings, Inc. (NASDAQ:...
The Law Office of Joseph Klein is investigating the Board of Directors of Prospect Medical Holdings, Inc. (NasdaqGM: PZZ) for possible breaches of fiduciary duty and other...
Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Prospect Medical Holdings, Inc. (“Prospect...
The Law Office of Vincent Wong is investigating the Board of Directors of Prospect Medical Holdings, Inc. (NasdaqGM: PZZ) for possible breaches of fiduciary duty and other...
Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Prospect Medical Holdings, Inc. (“Prospect” or the...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Die zuletzt besuchten Aktien werden in diesem Feld angezeigt, so dass Sie leicht zu den Aktien zurückkehren können, die Sie zuvor angesehen haben.
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
